Literature DB >> 33047257

Effectiveness of chlorthalidone/amiloride versus losartan in patients with stage I hypertension and diabetes mellitus: results from the PREVER-treatment randomized controlled trial.

Flávio D Fuchs1, Luiz C N Scala2, José F Vilela-Martin3, Paul K Whelton4, Carlos E Poli-de-Figueiredo5, Ricardo Pereira E Silva6, Miguel Gus1, Luiz A Bortolotto7, Fernanda M Consolim-Colombo7, Rosane P Schlatter8, José E Cesarino9, Iran Castro10, José A Figueiredo Neto11, Hilton Chaves12, André A Steffens13, João G Alves14, Andréa A Brandão15, Marcos R de Sousa16, Paulo C Jardim17, Leila B Moreira8, Roberto S Franco18, Marco M Gomes19, Abrahão Afiune Neto20, Felipe C Fuchs1, Dario C Sobral Filho21, Antônio C Nóbrega22, Fernando Nobre23, Otávio Berwanger24, Sandra C Fuchs25.   

Abstract

AIMS: To compare the blood pressure (BP)-lowering efficacy of a chlorthalidone/amiloride combination pill with losartan, during initial management of JNC 7 Stage I hypertension in patients with type 2 diabetes mellitus.
METHODS: In an a priori subgroup analysis of a randomized, double-blind, controlled trial, volunteers aged 30-70 years, with stage I hypertension and diabetes mellitus, were randomized to 12.5/2.5 mg of chlorthalidone/amiloride (N = 47) or 50 mg of losartan (N = 50), and followed for 18 months in 21 clinical centers. If BP remained uncontrolled after three months, study medication dose was doubled, and if uncontrolled after six months, amlodipine (5 and 10 mg) and propranolol (40 and 80 mg BID) were added as open label drugs in a progressive fashion.
RESULTS: Systolic BP decreased to a greater extent in participants allocated to diuretics compared to losartan (P < 0.001). After 18 months of follow-up, systolic BP was 128.4 ± 10.3 mmHg in the diuretic group versus 133.5 ± 8.0 in the losartan group (P < 0.01). In the diuretic group, 36 out of 43 participants (83.7%) had a JNC 7 normal BP, compared to 31/47 (66%) in the losartan group (P = 0.089). Serum cholesterol was higher in the diuretic arm at the end of the trial. Other biochemical parameters and reports of adverse events did not differ by treatment.
CONCLUSIONS: Treatment of hypertension based on a combination of chlorthalidone and amiloride is more effective for BP lowering compared to losartan in patients with diabetes mellitus and hypertension. TRIAL REGISTRATION: Clinical trials registration number: NCT00971165.

Entities:  

Keywords:  Amiloride; Chlorthalidone; Diabetes; Drug treatment; Hypertension; Losartan

Year:  2020        PMID: 33047257     DOI: 10.1007/s00592-020-01611-8

Source DB:  PubMed          Journal:  Acta Diabetol        ISSN: 0940-5429            Impact factor:   4.280


  12 in total

1.  Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis.

Authors:  Jun Cheng; Wen Zhang; Xiaohui Zhang; Fei Han; Xiayu Li; Xuelin He; Qun Li; Jianghua Chen
Journal:  JAMA Intern Med       Date:  2014-05       Impact factor: 21.873

Review 2.  Effects of blood-pressure-lowering treatment on outcome incidence in hypertension: 10 - Should blood pressure management differ in hypertensive patients with and without diabetes mellitus? Overview and meta-analyses of randomized trials.

Authors:  Costas Thomopoulos; Gianfranco Parati; Alberto Zanchetti
Journal:  J Hypertens       Date:  2017-05       Impact factor: 4.844

3.  2018 ESC/ESH Guidelines for the management of arterial hypertension.

Authors:  Bryan Williams; Giuseppe Mancia; Wilko Spiering; Enrico Agabiti Rosei; Michel Azizi; Michel Burnier; Denis L Clement; Antonio Coca; Giovanni de Simone; Anna Dominiczak; Thomas Kahan; Felix Mahfoud; Josep Redon; Luis Ruilope; Alberto Zanchetti; Mary Kerins; Sverre E Kjeldsen; Reinhold Kreutz; Stephane Laurent; Gregory Y H Lip; Richard McManus; Krzysztof Narkiewicz; Frank Ruschitzka; Roland E Schmieder; Evgeny Shlyakhto; Costas Tsioufis; Victor Aboyans; Ileana Desormais
Journal:  Eur Heart J       Date:  2018-09-01       Impact factor: 29.983

4.  A comparison between diuretics and angiotensin-receptor blocker agents in patients with stage I hypertension (PREVER-treatment trial): study protocol for a randomized double-blind controlled trial.

Authors:  Flávio D Fuchs; Sandra C Fuchs; Leila B Moreira; Miguel Gus; Antônio C Nóbrega; Carlos E Poli-de-Figueiredo; Décio Mion; Luiz Bortolotto; Fernanda Consolim-Colombo; Fernando Nobre; Eduardo Barbosa Coelho; José F Vilela-Martin; Heitor Moreno; Evandro José Cesarino; Roberto Franco; Andréa Araujo Brandão; Marcos R de Sousa; Antônio Luiz Pinho Ribeiro; Paulo Cesar Jardim; Abrahão Afiune Neto; Luiz César N Scala; Marco Mota; Hilton Chaves; João Guilherme Alves; Dario C Sobral Filho; Ricardo Pereira e Silva; José A Figueiredo Neto; Maria Cláudia Irigoyen; Iran Castro; André Avelino Steffens; Rosane Schlatter; Renato Bandeira de Mello; Francisca Mosele; Flávia Ghizzoni; Otávio Berwanger
Journal:  Trials       Date:  2011-02-24       Impact factor: 2.279

5.  Effectiveness of chlorthalidone/amiloride versus losartan in patients with stage I hypertension: results from the PREVER-treatment randomized trial.

Authors:  Flávio D Fuchs; Luiz César N Scala; José F Vilela-Martin; Renato Bandeira de Mello; Francisca Mosele; Paul K Whelton; Carlos E Poli-de-Figueiredo; Paulo Ricardo de Alencastro; Ricardo Pereira E Silva; Miguel Gus; Luiz Aparecido Bortolotto; Rosane Schlatter; Evandro José Cesarino; Iran Castro; José A Figueiredo Neto; Hilton Chaves; André Avelino Steffens; João Guilherme Alves; Andréa Araujo Brandão; Marcos R de Sousa; Paulo Cesar Jardim; Leila B Moreira; Roberto Silva Franco; Marco Mota Gomes; Abrahão Afiune Neto; Felipe Costa Fuchs; Dario C Sobral Filho; Antônio C Nóbrega; Fernando Nobre; Otávio Berwanger; Sandra C Fuchs
Journal:  J Hypertens       Date:  2016-04       Impact factor: 4.844

Review 6.  Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients.

Authors:  Laura C van Vark; Michel Bertrand; K Martijn Akkerhuis; Jasper J Brugts; Kim Fox; Jean-Jacques Mourad; Eric Boersma
Journal:  Eur Heart J       Date:  2012-04-17       Impact factor: 29.983

Review 7.  Angiotensin receptor blockers and risk of myocardial infarction: meta-analyses and trial sequential analyses of 147 020 patients from randomised trials.

Authors:  Sripal Bangalore; Sunil Kumar; Jørn Wetterslev; Franz H Messerli
Journal:  BMJ       Date:  2011-04-26

Review 8.  2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

Authors:  Paul K Whelton; Robert M Carey; Wilbert S Aronow; Donald E Casey; Karen J Collins; Cheryl Dennison Himmelfarb; Sondra M DePalma; Samuel Gidding; Kenneth A Jamerson; Daniel W Jones; Eric J MacLaughlin; Paul Muntner; Bruce Ovbiagele; Sidney C Smith; Crystal C Spencer; Randall S Stafford; Sandra J Taler; Randal J Thomas; Kim A Williams; Jeff D Williamson; Jackson T Wright
Journal:  Hypertension       Date:  2017-11-13       Impact factor: 9.897

Review 9.  Angiotensin receptor blockers for prevention of cardiovascular disease: where does the evidence stand?

Authors:  Flávio Danni Fuchs; James J DiNicolantonio
Journal:  Open Heart       Date:  2015-04-10

Review 10.  Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies.

Authors:  M R Law; J K Morris; N J Wald
Journal:  BMJ       Date:  2009-05-19
View more
  3 in total

1.  First-line combination therapy versus first-line monotherapy for primary hypertension.

Authors:  Javier Garjón; Luis Carlos Saiz; Ana Azparren; Idoia Gaminde; Mª José Ariz; Juan Erviti
Journal:  Cochrane Database Syst Rev       Date:  2020-02-06

2.  Amiloride ameliorates muscle wasting in cancer cachexia through inhibiting tumor-derived exosome release.

Authors:  Lin Zhou; Tong Zhang; Wei Shao; Ruohan Lu; Lin Wang; Haisheng Liu; Bin Jiang; Shiqin Li; Huiqin Zhuo; Suheng Wang; Qinxi Li; Caihua Huang; Donghai Lin
Journal:  Skelet Muscle       Date:  2021-07-06       Impact factor: 4.912

3.  Hypertension prevalence in the All of Us Research Program among groups traditionally underrepresented in medical research.

Authors:  Paulette D Chandler; Cheryl R Clark; Guohai Zhou; Nyia L Noel; Confidence Achilike; Lizette Mendez; Andrea H Ramirez; Roxana Loperena-Cortes; Kelsey Mayo; Elizabeth Cohn; Lucila Ohno-Machado; Eric Boerwinkle; Mine Cicek; Jun Qian; Sheri Schully; Francis Ratsimbazafy; Stephen Mockrin; Kelly Gebo; Julien J Dedier; Shawn N Murphy; Jordan W Smoller; Elizabeth W Karlson
Journal:  Sci Rep       Date:  2021-06-22       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.